Because the great majority of KRAS-variant double primary patients in this study developed breast cancer before their ovarian cancer, it appears that there could have been an opportunity for ovarian cancer prevention through chemoprevention (oral contraceptives) and/or prophylactic oophorectomy for these women. The gene discussed is KRAS; the disease is ovarian cancer.